239 related articles for article (PubMed ID: 33732990)
1. Characteristics of Patients with End-Stage Kidney Disease in ADPKD.
Shukoor SS; Vaughan LE; Edwards ME; Lavu S; Kline TL; Senum SR; Mkhaimer Y; Zaatari G; Irazabal MV; Neal R; Hogan MC; Zoghby ZM; Harris PC; Torres VE; Chebib FT
Kidney Int Rep; 2021 Mar; 6(3):755-767. PubMed ID: 33732990
[TBL] [Abstract][Full Text] [Related]
2. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
[TBL] [Abstract][Full Text] [Related]
3. The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
Lavu S; Vaughan LE; Senum SR; Kline TL; Chapman AB; Perrone RD; Mrug M; Braun WE; Steinman TI; Rahbari-Oskoui FF; Brosnahan GM; Bae KT; Landsittel D; Chebib FT; Yu AS; Torres VE; ; Harris PC
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32634120
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
[TBL] [Abstract][Full Text] [Related]
5. Germline Mutations for Kidney Volume in ADPKD.
Kataoka H; Yoshida R; Iwasa N; Sato M; Manabe S; Kawachi K; Makabe S; Akihisa T; Ushio Y; Teraoka A; Tsuchiya K; Nitta K; Mochizuki T
Kidney Int Rep; 2022 Mar; 7(3):537-546. PubMed ID: 35257066
[TBL] [Abstract][Full Text] [Related]
6. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
[TBL] [Abstract][Full Text] [Related]
7. Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease.
Heyer CM; Sundsbak JL; Abebe KZ; Chapman AB; Torres VE; Grantham JJ; Bae KT; Schrier RW; Perrone RD; Braun WE; Steinman TI; Mrug M; Yu AS; Brosnahan G; Hopp K; Irazabal MV; Bennett WM; Flessner MF; Moore CG; Landsittel D; Harris PC;
J Am Soc Nephrol; 2016 Sep; 27(9):2872-84. PubMed ID: 26823553
[TBL] [Abstract][Full Text] [Related]
8. Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry.
Breysem L; De Keyzer F; Schellekens P; Dachy A; De Rechter S; Janssens P; Vennekens R; Bammens B; Irazabal MV; Van Ongeval C; Harris PC; Mekahli D;
Clin J Am Soc Nephrol; 2023 Feb; 18(5):581-91. PubMed ID: 36800517
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging based kidney volume assessment for risk stratification in pediatric autosomal dominant polycystic kidney disease.
Yilmaz K; Saygili S; Canpolat N; Akgun-Dogan O; Yuruk Yildirim ZN; Cicek-Oksuz RY; Oner HA; Aksu B; Akyel NG; Oguzhan-Hamis O; Dursun H; Yavuz S; Cicek N; Akinci N; Karabag Yilmaz E; Agbas A; Nayir AN; Konukoglu D; Kurugoglu S; Sever L; Caliskan S
Front Pediatr; 2024; 12():1357365. PubMed ID: 38464892
[TBL] [Abstract][Full Text] [Related]
10. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
[TBL] [Abstract][Full Text] [Related]
11. Magnetic Resonance Kidney Parenchyma-T2 as a Novel Imaging Biomarker for Autosomal Dominant Polycystic Kidney Disease.
Siedek F; Grundmann F; Weiss K; Pinto Dos Santos D; Arjune S; Haneder S; Persigehl T; Müller RU; Baessler B
Invest Radiol; 2020 Apr; 55(4):217-225. PubMed ID: 31876626
[TBL] [Abstract][Full Text] [Related]
12. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
13. Estimation of Changes in Kidney Volume Growth Rate in ADPKD.
Higashihara E; Fukuhara H; Ouyang J; Lee J; Nutahara K; Tanbo M; Yamaguchi T; Taguchi S; Muto S; Kaname S; Miyazaki I; Horie S
Kidney Int Rep; 2020 Sep; 5(9):1459-1471. PubMed ID: 32954070
[TBL] [Abstract][Full Text] [Related]
14. Predicting Future Renal Function Decline in Patients with Autosomal Dominant Polycystic Kidney Disease Using Mayo Clinic Classification.
Borrego Utiel FJ; Esteban de la Rosa RJ; Merino García E; Medina Benítez A; Polo Moyano A; Moriana Domínguez C; Morales García AI; Bravo Soto JA
Am J Nephrol; 2021; 52(8):630-641. PubMed ID: 34518464
[TBL] [Abstract][Full Text] [Related]
15. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
16. A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease.
Simms RJ; Doshi T; Metherall P; Ryan D; Wright P; Gruel N; van Gastel MDA; Gansevoort RT; Tindale W; Ong ACM
Eur Radiol; 2019 Aug; 29(8):4188-4197. PubMed ID: 30666443
[TBL] [Abstract][Full Text] [Related]
17. Spleen phenotype in autosomal dominant polycystic kidney disease.
Yin X; Prince WK; Blumenfeld JD; Zhang W; Donahue S; Bobb WO; Rennert H; Askin G; Barash I; Prince MR
Clin Radiol; 2019 Dec; 74(12):975.e17-975.e24. PubMed ID: 31563290
[TBL] [Abstract][Full Text] [Related]
18. Mineral bone disease in autosomal dominant polycystic kidney disease.
Gitomer B; Pereira R; Salusky IB; Stoneback JW; Isakova T; Cai X; Dalrymple LS; Ofsthun N; You Z; Malluche HH; Maddux F; George D; Torres V; Chapman A; Steinman TI; Wolf M; Chonchol M
Kidney Int; 2021 Apr; 99(4):977-985. PubMed ID: 32926884
[TBL] [Abstract][Full Text] [Related]
19. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
[TBL] [Abstract][Full Text] [Related]
20. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan.
Higashihara E; Horie S; Muto S; Kawano H; Tambo M; Yamaguchi T; Taguchi S; Kaname S; Yokoyama K; Yoshioka T; Furukawa T; Fukuhara H
Am J Nephrol; 2020; 51(11):881-890. PubMed ID: 33227802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
